Red Dot distinction for Owen Mumford’s Aidaptus Auto-injector
Medical device innovator Owen Mumford has been awarded a distinction in the Red Dot awards.
The Oxfordshire-based firm was awarded the Product Design 2023 award for its Aidaptus single-use auto-injector, which launched in 2021.
Aidaptus, which is designed, developed and manufactured by Owen Mumford was created to administer a variety of drugs and biologics which require subcutaneous delivery (meaning it is injected into the fatty layer between the skin and the muscle).
It won the award for unique and distinct design elements, including auto adjust stopper sensing technonly which uses a self-adjusting plunger that automatically adapts to different fill volumes in each syringe, with no change parts required.
Because Aidaptus is designed to accommodate both 1ml and 2.25 ml prefilled glass, it offers pharmaceutical companies one solution for a variety of drug formulations, while its two-step injection process makes it easier to use, allowing patients to administer their own treatments in a home setting.
Owen Mumford’s CEO, Jarl Severn said: “Red Dot is one of the most prestigious design competitions that is highly competitive, and we are honoured to be globally recognised with distinction in the Product Design 2023 category.
“We have previously enjoyed this accolade for our Unifine® Pentips® Plus pen needle and today’s news further underscores our ongoing pursuit and commitment to excellence in design.”
Read more - Owen Mumford appoints former Circassia VP as R&D Director
The Red Dot award has a been running for more than 60 years, bringing in around 20,000 entries per year making it one of the biggest design competitions in the world. Its panel of more than 40 international expert judges award excellent design across a wide variety of products on an annual basis. The “Red Dot” accolade has become established internationally as one of the most sought-after seals of quality for good design.
Michael Earl, Director, Owen Mumford Pharmaceutical Services said: “Our Aidaptus auto-injector platform has been designed to reduce complexity and provide a flexible solution for pharmaceutical and biotechnology companies who are developing a variety of drug formulations for subcutaneous delivery.
“It tackles the challenges of changes to drug formulation or injected volume and can therefore help reduce risk during drug development and lifecycle management. In addition, Aidaptus will help patients to self-administer their individual therapies for diseases such as rheumatoid arthritis, Crohn’s disease and multiple sclerosis, using a simple and easy to use device.”
The device will be manufactured at factories in Malaysia and the firm’s new production facility in Witney, Oxfordshire which is due for completion later this year. Owen Mumford is collaborating with Stevanato Group for moulding and assembly of Aidaptus.
Read more - Oxford Innovation invests in 3D printed biometric implants stimulating bone growth
